BRIEF-Pfizer Says CHMP Of EMA Recommended Against Expanding Use Of Sutent
February 23, 2018 at 08:37 AM EST
* PFIZER ANNOUNCES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR SUTENT® (SUNITINIB) IN ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA
